Boehringer Ingelheim reports 16% H1 growth driven by Jardiance sales

Boehringer Ingelheim achieved 16% revenue growth in the first half of 2026, primarily fueled by strong performance in its human pharmaceuticals division, specifically the diabetes drug Jardiance. The company's veterinary segment underperformed relative to the human health business, highlighting a divergence in divisional growth trajectories.